Article

(2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterole-mia: Recent and Emerging Therapeutic Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets. pp. 1018-1028. ISSN 18715303 (ISSN)

(2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. Endocrine, metabolic & immune disorders drug targets. pp. 1018-1028. ISSN 2212-3873 (Electronic) 1871-5303 (Linking)

(2021) Epigenetic aspects of multiple sclerosis and future therapeutic options. International Journal of Neuroscience. pp. 56-64. ISSN 0020-7454

(2020) Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches. Current Gene Therapy. pp. 386-394. ISSN 1566-5232

(2020) MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers. Current Cancer Therapy Reviews. pp. 269-275. ISSN 1573-3947

(2020) The atherogenic role of immune cells in familial hypercholesterolemia. Iubmb Life. pp. 782-789. ISSN 1521-6543

(2020) A novel variant in C5ORF42 gene is associated with Joubert syndrome. Molecular Biology Reports. pp. 4099-4103. ISSN 0301-4851

(2019) Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular Neurobiology. pp. 4799-4811. ISSN 0893-7648

(2019) Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies. Iubmb Life. pp. 1221-1229. ISSN 1521-6543

(2019) Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson's disease and epigenetic-based therapies. Journal of Cellular Physiology. pp. 19307-19319. ISSN 0021-9541

(2019) Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review. Journal of Cellular Biochemistry. pp. 8891-8898. ISSN 0730-2312

(2019) Roles of E6 and E7 Human Papillomavirus Proteins in Molecular Pathogenesis of Cervical Cancer. Current Protein & Peptide Science. pp. 926-934. ISSN 1389-2037